Jean Jacques Bienaime holds the role of Director at Keros Therapeutics, Inc. (KROS). Bienaime's filing history also covers Ascendis Pharma A/S (ASND) and Immunome Inc. (IMNM). Bienaime has reported 20 insider filings with the SEC since 2025. The most recent filing was in August 2026.
Every role Jean Jacques Bienaime has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Keros Therapeutics, Inc. (KROS)4 filingsAscendis Pharma A/S (ASND)2 filingsImmunome Inc. (IMNM)2 filingsINCYTE CORP (INCY)1 filingUpdated Aug 31, 2026
Jean Jacques Bienaime is Director of Keros Therapeutics, Inc. (KROS). 20 SEC Form 4 filings on record going back to 2025, most recently on 19 August 2026. Most recent open-market trade: bought $10K of KROS on 19 August 2026. Lifetime open-market purchases: $1.17M. Lifetime open-market sales: $204K. Historical track record: 2/5 stars across 9 tracked purchases.
Every recent SEC Form 4 transaction Jean Jacques Bienaime has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★☆☆☆ (2/5) |
| Total purchases tracked | 9 |
| Purchases with forward-return data | 9 |
| 30-day win rate | 56% |
| 90-day win rate | 56% |
| Avg 5-day return | -2.73% |
| Avg 30-day return | +0.23% |
| Avg 90-day return | -1.34% |
| Best 30-day return |
InsiderAlpha's records for Jean Jacques Bienaime go back to 2025: 20 primary Form 4 filings, an average of 10.0 per year. The typical open-market purchase is $59K (20 buys totaling $1.17M). The largest single buy on record is $270K of ASND in 2026. Sales side: 2 recorded sales totaling $204K, so the filing history runs buy-heavy by dollar value. 9 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Jean Jacques Bienaime files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Jean Jacques Bienaime is a corporate insider, tracked as Director of Keros Therapeutics, Inc. (KROS). InsiderAlpha holds 20 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
9 primary Form 4 filings in the last 90 days, covering 4 companies.
Recorded transactions: 20 open-market purchases ($1.17M) and 2 open-market sales ($204K) across all tracked filings.
Across 9 tracked purchases, Jean Jacques Bienaime averaged +0.2% avg 30-day return with a 56% 30-day win rate. InsiderAlpha rates the track record at 2/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
| +10.57% |